Article

Ligands for Retinoic Acid Receptors Are Elevated in Osteoarthritis and May Contribute to Pathologic Processes in the Osteoarthritic Joint

AstraZeneca Pharmaceuticals, Cheshire, UK.
Arthritis & Rheumatology (Impact Factor: 7.87). 06/2009; 60(6):1722-32. DOI: 10.1002/art.24550
Source: PubMed

ABSTRACT Vitamin A derivatives, including all-trans-retinoic acid (ATRA), have a well-established role during skeletal development and limb formation and have been shown to have profound effects on chondrocyte phenotype. The aim of this study was to elucidate the effects of retinoids and components of the retinoid metabolic pathway on chondrocyte phenotype in the tibiofemoral joints of patients with osteoarthritis (OA), to show that the retinoids can have multiple effects relevant to the OA disease process.
Human explant tissue and a chondrocyte-like cell line were treated with ATRA, and the responses of 4 key markers of chondrocyte phenotype were analyzed. In addition, the effects of ATRA on a number of novel genes associated with OA were assessed using a low-density microarray containing 80 disease marker genes.
Vitamin A metabolite levels were elevated in synovial fluid, serum, and cartilage from patients with OA. Expression profiling of a retinoic acid receptor alpha coactivator protein, P/CAF, demonstrated elevated expression in patients with OA, suggesting the potential for increased signaling via the retinoid receptors in the disease. ATRA increased the levels of matrix metalloproteinase 13 and aggrecanase activity in human cartilage explants and in a human chondrocyte cell line. Furthermore, ATRA altered the expression of a wide range of relevant genes, including the types I, II, IX, and XI collagen genes, toward a nonchondrogenic and OA-like phenotype.
These results suggest that retinoid signaling could have a central role in OA, and that components of the pathway may provide potential disease biomarkers or targets for therapeutic intervention.

0 Followers
 · 
141 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objective: Osteoarthritis (OA) is a serious disease of the entire joint, characterized by degeneration of articular cartilage, subchondral bone changes, osteophyte formation and synovial hyperplasia. Currently, there are no pharmaceutical treatments to slow disease progression, resulting in greatly reduced quality of life for patients and the need for joint replacement surgeries in many cases. The lack of available treatments for OA is partially due to our incomplete understanding of the molecular mechanisms promoting disease initiation and progression. Here we identify the nuclear receptor PPARdelta as a promoter of cartilage degeneration in a mouse model of post-traumatic OA.Methods: Mouse chondrocytes and knee explants were treated with a pharmacological agonist of PPARdelta (GW501516) to evaluate changes in gene expression, histology and matrix glycosaminoglycan breakdown. In vivo, PPARdelta was specifically deleted in the cartilage of mice. Mutant and control mice were compared after destabilization of medial meniscus (DMM) surgery by histopathological scoring (OARSI) and immunohistochemistry.Results: In vitro, PPARdelta activation by GW501516 results in increased expression of several proteases in chondrocytes as well as aggrecan degradation and glycosaminoglycan release in knee joint explants. In vivo, cartilage specific Ppard knockout mice do not display any abnormalities of skeletal development, but show marked protection in the DMM model of post-traumatic OA (compared to control littermates). OARSI scoring and immunohistochemistry confirm strong protection of mutant mice from DMM-induced cartilage degeneration.Conclusion: These data demonstrate a catabolic role of endogenous PPARdelta in post-traumatic OA and suggest that pharmacological inhibition of PPARdelta is a promising therapeutic strategy. © 2014 American College of Rheumatology.
    10/2014; 22. DOI:10.1002/art.38915
  • [Show abstract] [Hide abstract]
    ABSTRACT: Vitamin A (retinol) is ingested as either retinyl esters or carotenoids and metabolized to active compounds, such as 11-cis-retinal, which is important for vision, and all-trans-retinoic acid (ATRA), which is the primary mediator of biological actions of vitamin A. ATRA binds to retinoic acid receptors (RARs), which heterodimerize with retinoid X receptors (RXRs). RAR-RXR heterodimers function as transcription factors, binding RAR responsive elements in promoters of different genes. Numerous cellular functions, including bone cell functions, are mediated by vitamin A; however, it has long been recognized that increased levels of vitamin A can have deleterious effects on bone resulting in increased skeletal fragility. Bone mass is dependent on the balance between bone resorption and bone formation. A decrease in bone mass may be caused by either an excess of resorption or decreased bone formation. Early studies indicated that the primary skeletal effect of vitamin A was to increase bone resorption, but later studies have shown that vitamin A can not only stimulate the formation of bone resorbing osteoclasts, but inhibit their formation as well. Effects of vitamin A on bone formation have not been studied in as great a detail and are not as well characterized as effects on bone resorption. Several epidemiological studies have shown an association between vitamin A, decreased bone mass, and osteoporotic fractures, but the data are not conclusive, for other studies have found no associations, and some studies have suggested that vitamin A primarily promotes skeletal health. In this presentation, we have summarized how vitamin A is absorbed, metabolized, and functions intracellularly. Vitamin A deficiency and excess are introduced, and detailed descriptions of clinical and pre-clinical studies of the effects of vitamin A on the skeleton are presented.
    Endocrine reviews 05/2013; 34(6). DOI:10.1210/er.2012-1071 · 19.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this review a discussion of the usual procedures used to synthesize retinoids is followed by an overview of the structure-activity relationships of these molecules. The discussion is then focused on the role and impact of retinoids on metabolic disorders with a particular emphasis on obesity, diabetes, and the metabolic syndrome. In these areas, both natural and synthetic retinoids that are being studied are reviewed and areas where likely future research will occur are suggested. This article is part of a Special Issue entitled Retinoid and Lipid Metabolism.
    Biochimica et Biophysica Acta 04/2011; 1821(1):3-9. DOI:10.1016/j.bbalip.2011.04.007 · 4.66 Impact Factor